In the RNA field, many companies are facing challenges when advancing research projects due to time, expertise, and resource constraints. Many biotechnology firms are seeking to overcome these hurdles by partnering with larger pharmaceutical organisations, to leverage the expertise and strengths of other collaborators to drive innovation and expedite the development of novel RNA-based therapies.
Their Project Leader and specialist in RNA-based therapeutic development, Erica Cirri PhD., appeared in the Summer 2025 issue of European Biopharmaceutical Review (EBR), discussing how industry collaborations between smaller biotechnology firms and larger pharmaceutical organisations is helping to drive innovation and technological advancements in RNA therapeutics. She highlights the strategic partnerships in RNA vaccine development that are helping to transform infectious disease management, precision medicine in oncology applications, and the opportunities for self-amplifying RNA (saRNA).
Tebubio is home to a dedicated Contract Research Services (CRS) Laboratory, which provides high-quality, tailored solutions for RNA synthesis, delivery and expression.
Get in touch with the Tebubio team and find out how we can support your RNA therapeutics development today.
You can read an excerpt of Erica’s article in EBR below, and view the full piece in the Summer 2025 issue.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
